AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Physicians’ Education Resource® to Present Molecular Tumor Board on EGFR Mutation Positive Lung Cancers

March 13, 2019

CRANBURY, N.J.--(BUSINESS WIRE)--Mar 13, 2019--Physicians’ Education Resource ® (PER ® ), a worldwide leader in continuing medical education (CME), will conduct the live CME-accredited activity, Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data Into Patient Care, as a satellite symposium adjunct to the AACR Annual Meeting 2019. The symposium will take place on Monday, April 1, from 7-9 p.m. at the Atlanta Hyatt Regency in Georgia and will be chaired by David R. Gandara, M.D., professor of medicine in the division of hematology/oncology director of the thoracic oncology program, senior advisor to the director at the University of California Davis Comprehensive Cancer Center.

“Diagnosis, treatment and management of EGFR mutation-positive non-small cell lung cancer (NSCLC) continues to evolve as new evidence develops,” said Phil Talamo, president of PER®. “This activity will explore these recent advances and provide oncologists with expert advice on optimal treatment paradigms for patients with NSCLC and EGFR mutations by using an exciting case-based format.”

This cutting-edge symposium will consist of a panel of world-class experts in lung cancer will review recent practice-changing data and state-of-the-art approaches for patients with EGFR mutation-positive NSCLC, with an emphasis on examining the evidence and trial data and how to interpret and apply those data in their practice. Oncologists who attend this symposium will gain insights into the use of liquid-based and tissue-based testing methods to choose the best therapy for patients with EGFR mutation-positive NSCLC, learn about the latest clinical data on first-line treatment of patients with NSCLC and EGFR mutations, and approaches and strategies to manage treatments-related toxicities in patients with EGFR mutation-positive NSCLC.

This live activity is accredited by the Accreditation Council for Continuing Medical Education for 2.0 AMA PRA Category 1 Credits™ for physicians. For more information and to register, click here.

About Physicians’ Education Resource ® (PER ® )

Since 1995, PER ® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER ® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside of oncology, PER ® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER ® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER ® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005675/en/

CONTACT: PER® Media:

Alexandra Ventura, 609-716-7777, ext. 121

aventura@mjhassoc.comJohn Patricolo, 609-325-4630

jpatricolo@mjhassoc.com

KEYWORD: UNITED STATES NORTH AMERICA GEORGIA NEW JERSEY

INDUSTRY KEYWORD: HEALTH HOSPITALS ONCOLOGY PROFESSIONAL SERVICES CONSULTING OTHER PROFESSIONAL SERVICES RESEARCH OTHER SCIENCE SCIENCE GENERAL HEALTH

SOURCE: Physicians’ Education Resource

Copyright Business Wire 2019.

PUB: 03/13/2019 01:11 PM/DISC: 03/13/2019 01:11 PM

http://www.businesswire.com/news/home/20190313005675/en